PepGen

PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.